Advanced

Haemate P/Humate-P: a systematic review.

Berntorp, Erik LU (2009) In Thrombosis Research 124 Suppl 1(Nov). p.11-14
Abstract
Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII)-containing concentrate that was pasteurized to reduce the risk of virus infection, was developed in the 1970s and approved for use in Germany in 1981. Today, Haemate P is marketed in over 35 countries worldwide for on-demand treatment and long-term prophylaxis in patients with von Willebrand disease (VWD) or haemophilia A. With more than 25 years of clinical experience, Haemate P has demonstrated predictable pharmacokinetics, consistent haemostatic efficacy, and an excellent safety profile in paediatric and adult populations. Its VWF composition is quantitatively and qualitatively similar to that of normal plasma. The risk of virus transmission has... (More)
Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII)-containing concentrate that was pasteurized to reduce the risk of virus infection, was developed in the 1970s and approved for use in Germany in 1981. Today, Haemate P is marketed in over 35 countries worldwide for on-demand treatment and long-term prophylaxis in patients with von Willebrand disease (VWD) or haemophilia A. With more than 25 years of clinical experience, Haemate P has demonstrated predictable pharmacokinetics, consistent haemostatic efficacy, and an excellent safety profile in paediatric and adult populations. Its VWF composition is quantitatively and qualitatively similar to that of normal plasma. The risk of virus transmission has been minimized, and treatment-related adverse events are rare. Only a very low incidence of thromboembolic events has been reported. Guidelines for dosing have been developed; optimal dosing depends on the goals of therapy, clinical setting, VWD type and severity, and other patient-related factors. Based on the extensive clinical experience with Haemate P, it has become the gold standard for replacement therapy in patients with VWD. Further studies will continue to explore its use in other clinical settings, including as immune tolerance induction therapy for patients with haemophilia A. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Thrombosis Research
volume
124 Suppl 1
issue
Nov
pages
11 - 14
publisher
Elsevier Ltd
external identifiers
  • wos:000272857600004
  • pmid:19944255
  • scopus:71549152209
ISSN
1879-2472
DOI
10.1016/S0049-3848(09)70152-5
language
English
LU publication?
yes
id
15748798-3045-4829-98da-7bbcf8650d7b (old id 1524195)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19944255?dopt=Abstract
date added to LUP
2010-01-07 16:11:24
date last changed
2017-10-01 04:56:07
@article{15748798-3045-4829-98da-7bbcf8650d7b,
  abstract     = {Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII)-containing concentrate that was pasteurized to reduce the risk of virus infection, was developed in the 1970s and approved for use in Germany in 1981. Today, Haemate P is marketed in over 35 countries worldwide for on-demand treatment and long-term prophylaxis in patients with von Willebrand disease (VWD) or haemophilia A. With more than 25 years of clinical experience, Haemate P has demonstrated predictable pharmacokinetics, consistent haemostatic efficacy, and an excellent safety profile in paediatric and adult populations. Its VWF composition is quantitatively and qualitatively similar to that of normal plasma. The risk of virus transmission has been minimized, and treatment-related adverse events are rare. Only a very low incidence of thromboembolic events has been reported. Guidelines for dosing have been developed; optimal dosing depends on the goals of therapy, clinical setting, VWD type and severity, and other patient-related factors. Based on the extensive clinical experience with Haemate P, it has become the gold standard for replacement therapy in patients with VWD. Further studies will continue to explore its use in other clinical settings, including as immune tolerance induction therapy for patients with haemophilia A.},
  author       = {Berntorp, Erik},
  issn         = {1879-2472},
  language     = {eng},
  number       = {Nov},
  pages        = {11--14},
  publisher    = {Elsevier Ltd},
  series       = {Thrombosis Research},
  title        = {Haemate P/Humate-P: a systematic review.},
  url          = {http://dx.doi.org/10.1016/S0049-3848(09)70152-5},
  volume       = {124 Suppl 1},
  year         = {2009},
}